Oracle Health Sciences InForm electronic data capture platform utilizes Proteus solution, enabling greater accuracy in measuring medication adherence during clinical trials.
Highly engaged patients that consistently take their prescribed medications as directed are the cornerstone of a successful clinical trial. Researchers have long struggled to effectively and efficiently validate adherence-relying on an arduous and often inaccurate combination of self-reporting and lab tests. To help health sciences organizations more effectively track and manage the use of medication during clinical trials, Oracle has introduced Oracle Health Sciences InForm Medication Adherence Insights Cloud Service.
This solution not only enables clinical trial sponsors to automatically capture precise and timely data about medication adherence, it can also help accelerate insight about drug efficacy and safety and speed clinical trials, which can, in turn, increase trial success rates.
News Facts
“Oracle Health Sciences InForm Medication Adherence Insights Cloud Service helps health sciences organizations effectively address two long-standing and complex challenges: measuring participant adherence to drug protocols and identifying the optimum dosing regimen for recommended use,” said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences. “This groundbreaking solution-the direct result of a collaboration between Oracle and Proteus Digital Health-is a powerful example of how we can rapidly combine our industry-leading clinical trial data capture and management solutions with emerging technologies, such as digital pills, to help health sciences organizations transform the drug development and approval process.”
“The medication adherence option uniquely addresses the most critical information in a clinical trial: ‘Did the patients use their medicine properly?’ Combining this powerful new data with the technology, analysis, and capabilities of Oracle Health Sciences creates a game-changing opportunity for drug development,” said Markus Christen, head of global development, Proteus Digital Health.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.